DNMT3A and heart failure: Furthermore, DNMT3A or TET2 mutations were associated with accelerated progression of heart failure (further reduction of left ventricular ejection fraction (LVEF), heart failure-related death or hospitalization) within a 3.5 years’ follow-up irrespective of ischemic/non-ischemic etiology [60].